Patents Assigned to Thomas Jefferson University
  • Patent number: 10772904
    Abstract: The present disclosure relates to compositions and methods for treating cancers using antisense (AS) nucleic acids directed against Insulin-like Growth Factor 1 Receptor (IGF-1R). The AS may be administered to the patients systemically, or may be used to produce an autologous cancer cell vaccine. In embodiments, the AS are provided in an implantable irradiated biodiffusion chamber comprising tumor cells and an effective amount of the AS. The chambers are irradiated and implanted in the abdomen of subjects and stimulate an immune response that attacks tumors distally. The compositions and methods disclosed herein may be used to treat many different kinds of cancer, for example glioblastoma.
    Type: Grant
    Filed: July 22, 2019
    Date of Patent: September 15, 2020
    Assignee: THOMAS JEFFERSON UNIVERSITY
    Inventors: David W. Andrews, Douglas C. Hooper
  • Publication number: 20200214621
    Abstract: Systems and methods for detecting patient movement and ensuring compliance with patient turning, comprising strap having at least a horizontal and one or more sensors positioned on the horizontal component; a display comprising a processor and a database, configured to receive information from the one or more sensors and to generate a timer to ensure patient turning at a predetermined time.
    Type: Application
    Filed: September 7, 2018
    Publication date: July 9, 2020
    Applicant: Thomas Jefferson University
    Inventors: Mark Keroles, Daniel S. Choi, Vinayak Rajandran, Adam Michael Hecht
  • Publication number: 20200202976
    Abstract: Methods of treating a disease by leveraging positive and negative correlations between tRNA-derived fragments (tRF) and messenger RNA (mRNA) wherein said correlations can be used to establish a level of granularity that is specific to a disease of interest wherein said disease-specific positive and negative correlations can allow a level of therapeutic intervention that will be unprecedented because it will have been informed by three dimensions: at least one mRNA of interest; at least one tRF that are positively/negatively correlated with it; and, the identity of the disease in which one wishes to modulate the abundance of the at least one mRNA of interest.
    Type: Application
    Filed: May 1, 2018
    Publication date: June 25, 2020
    Applicant: Thomas Jefferson University
    Inventors: Isidore Rigoutsos, Aristeidis G. Telonis
  • Publication number: 20200197487
    Abstract: Treatment of chronic neurodegenerative diseases such as multiple sclerosis (MS) remains a major challenge. Here we genetically engineer neural stem cells (NSCs) to produce a triply therapeutic cocktail comprising IL-10, NT-3, and LINGO-1-Fc, thus simultaneously targeting all mechanisms underlie chronicity of MS in the central nervous system (CNS): persistent inflammation, loss of trophic support for oligodendrocytes and neurons, and accumulation of neuroregeneration inhibitors. After transplantation, NSCs migrated into the CNS inflamed foci and delivered these therapeutic molecules in situ. NSCs transduced with one, two, or none of these molecules had no or limited effect when injected at the chronic stage of experimental autoimmune encephalomyelitis; cocktail -producing NSCs, in contrast, mediated the most effective recovery through inducing M2 macrophages/microglia, reducing astrogliosis, and promoting axonal integrity and endogenous oligodendrocyte/neuron differentiation.
    Type: Application
    Filed: May 7, 2018
    Publication date: June 25, 2020
    Applicant: Thomas Jefferson University
    Inventors: Guang-Xian Zhang, Yaping Yan, Xing Li
  • Patent number: 10689423
    Abstract: Provided herein are recombinant CTLA-4 binding proteins, which are, inter alia, useful for the treatment of cancer. The recombinant proteins provided herein are, inter alia, capable of binding CTLA-4 proteins on a tumor cell. In a first aspect, there is provided a recombinant CTLA-4 binding protein including (i) a CTLA-4 binding domain; (ii) a CTLA-4 binding domain masking peptide; and (iii) a cleavable peptide linker connecting the CTLA-4 binding domain masking peptide to the CTLA-4 binding domain. In another aspect, there is provided a dimerizing domain covalently attached to the CTLA-4 binding domain, wherein the binding protein domains are bound together.
    Type: Grant
    Filed: January 13, 2016
    Date of Patent: June 23, 2020
    Assignees: City of Hope, Thomas Jefferson University and Health System Innovation Pillar
    Inventors: John Williams, Ulrich Rodeck
  • Publication number: 20200190604
    Abstract: The present invention relates to systems, devices and methods for diagnosing cancer. In various embodiments, the present invention provides a method for quantifying a 5?-htRNA; a method for quantifying a 3?-htRNA; a method for obtaining a DNA library of 5?-htRNAs and a DNA library of 5?-htRNAs obtained therefrom; and a method for obtaining a DNA library of 3?-htRNAs and a DNA library of 3?-htRNAs obtained therefrom. The invention also teaches a method for determining the presence or absence of a cancer cell in a biological sample; a method of diagnosing cancer in a subject; and a method of prognosing cancer in a subject.
    Type: Application
    Filed: February 26, 2020
    Publication date: June 18, 2020
    Applicant: Thomas Jefferson University
    Inventors: Yohei Kirino, Shozo Honda
  • Patent number: 10682079
    Abstract: Methods and systems include a long-term implantable ultra-filtrate monitoring system that uses micro-porous membranes to produce an ultra-filtrate of tissue interstitial fluid or blood plasma. The ultra-filtrate is transported through a sensor to detect a level of analyte in the ultra-filtrate. The long-term implantable fluid monitoring system thus includes a first porous catheter, a second porous catheter, a sensor configured to measure an amount of analyte in fluid, and a pump configured to move fluid through the first porous catheter to the sensor and from the sensor through the second porous catheter.
    Type: Grant
    Filed: October 12, 2017
    Date of Patent: June 16, 2020
    Assignee: Thomas Jefferson University
    Inventors: Jeffrey I. Joseph, Amanda L. Joseph
  • Publication number: 20200164077
    Abstract: In one embodiment, a masked monoclonal antibody (mAb) is provided, the mAb, encoded by a nucleic acid sequence or an amino acid sequence molecule comprising a signal sequence, a masking epitope sequence, a linker sequence that is cleavable by a protease specific to a target tissue; and an antibody or a functional fragment thereof. In another embodiment, a masked monoclonal antibody (mAb) is provided, which includes a therapeutic mAb and a mask, the mask comprising protein A and protein L attached by a protease cleavable linker.
    Type: Application
    Filed: July 2, 2019
    Publication date: May 28, 2020
    Applicant: Thomas Jefferson University
    Inventors: John C. Williams, Cindy Zer, Kendra N. Avery, Ulrich Rodeck, Joshua M. Donaldson, Csaba Kari
  • Publication number: 20200164054
    Abstract: A CMV-based vaccine that promotes immune-mediated destruction of cancer through a onetime or repeated intratumoral administration of a recombinant CMV to generate a robust, long-lasting anti-tumor immune response.
    Type: Application
    Filed: December 21, 2016
    Publication date: May 28, 2020
    Applicant: THOMAS JEFFERSON UNIVERSITY
    Inventors: Christopher M. SNYDER, Daniel A. ERKES
  • Patent number: 10662480
    Abstract: The present invention relates to systems, devices and methods for diagnosing cancer. In various embodiments, the present invention provides a method for quantifying a 5?-htRNA; a method for quantifying a 3?-htRNA; a method for obtaining a DNA library of 5?-htRNAs and a DNA library of 5?-htRNAs obtained therefrom; and a method for obtaining a DNA library of 3?-htRNAs and a DNA library of 3?-htRNAs obtained therefrom. The invention also teaches a method for determining the presence or absence of a cancer cell in a biological sample; a method of diagnosing cancer in a subject; and a method of prognosing cancer in a subject.
    Type: Grant
    Filed: February 4, 2015
    Date of Patent: May 26, 2020
    Assignee: Thomas Jefferson University
    Inventors: Yohei Kirino, Shozo Honda
  • Patent number: 10619102
    Abstract: A thermal process for carbonizing hemp and reducing particle size, mechanically, by grinding or milling said carbonized hemp materials to generate a precise particle size hemp char and combining the hemp char particles with a polymer into a master batch.
    Type: Grant
    Filed: April 26, 2019
    Date of Patent: April 14, 2020
    Assignee: Thomas Jefferson University
    Inventor: Mark Sunderland
  • Patent number: 10602936
    Abstract: An implantable vital sign sensor including a housing including a first portion, the first portion defining a first open end, a second open end opposite the first end, and a lumen there through, the first portion being sized to be implanted substantially entirely within the blood vessel wall of the patient. A sensor module configured to measure a blood vessel blood pressure waveform is included, the sensor module having a proximal portion and a distal portion, the distal portion being insertable within the lumen and the proximal portion extending outward from the first open end.
    Type: Grant
    Filed: August 8, 2017
    Date of Patent: March 31, 2020
    Assignee: Thomas Jefferson University
    Inventor: Jeffrey I Joseph
  • Patent number: 10590126
    Abstract: A substance of Formula (I) for use as a medicament for the treatment of cardiovascular diseases, wherein R is nitrogen or carbon; R1 is selected from the group consisting of a hydrogen, a trifluoromethyl, a methyloxyphenyl, a phenyl, a C1-C3 phenylalkyl, a halogenated phenyl, a halogenated C1-C3 phenylalkyl, a trifluoromethyloxy, a trifluoromethyl oxyphenyl, and a C1-C3 pyridinylalkyl; R2 is selected from the group consisting of a C1-C3 alkyl alcohol optionally substituted with a C1-C3 alkoxyphenyl, a C1-C3 N-alkylmethanamine, a C1-C3 alkoxymethyl, a C1-C3 phenylalkoxymethyl, a C1-C3 cyclopropylalkoxymethyl, and a methoxyethoxymethyl; and R3 is a phenyl or a methoxypyridinyl; and R4 is selected from the group consisting of a hydrogen, a cyano, a C1-C3 sulfonyl, a nitro, and a trifluoromethyl.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: March 17, 2020
    Assignee: THOMAS JEFFERSON UNIVERSITY
    Inventor: Paul F. Bray
  • Publication number: 20200064338
    Abstract: A method for measuring kinetics of Ca2+ flux in differentially responding T cells that form monolayer on the glass surface in response to antigenic peptides or live target cells comprising: immobilizing T cells labeled with Ca2+ sensitive fluorophore on the glass bottom of a well, covered with capturing antibody or a capturing protein that bind to non-stimulatory T-cell surface receptor; adding to the well a single or multiple peptide epitopes that binds to the cell surface MHC molecules to be presented for recognition by cognate T cells; the stimulatory signal could also be delivered by live target cells that display peptide epitope(s); wherein the recognition of stimulatory of pMHC by the peptide specific T cells leads to increase of intracellular Ca2+ level and fluorescence intensity in the responding T cells.
    Type: Application
    Filed: May 14, 2018
    Publication date: February 27, 2020
    Applicant: Thomas Jefferson University
    Inventors: Yuri Sykulev, Nadezhda Anikeyeva
  • Publication number: 20200066414
    Abstract: The system comprises a control module, wherein a medical professional connects to a patient to initiate a telehealth appointment. In certain embodiments, the system comprises a control module accessible to a medical professional, software or an app loaded on the control module and on a second user (patient) device. By running the software or app on both devices, the medical professional and the patient can initiate a connection between the two devices.
    Type: Application
    Filed: October 25, 2017
    Publication date: February 27, 2020
    Applicant: Thomas Jefferson University
    Inventors: Robert NEFF, Judd HOLLANDER, Neil Dominic GOMES
  • Publication number: 20200054761
    Abstract: The present disclosure provides methods and compositions for enhancing the treatment of a cancer, particularly in a human subject, by administering antibody drug conjugates (ADCs) to inhibit or kill specific myeloid/monocyte/macrophage-lineage cells. The myeloid/monocyte/macrophage-lineage cells are identified, for example, by expression of one or more of the scavenger receptors CD204 and CD163, and/or mannose receptor-1 (CD206).
    Type: Application
    Filed: February 22, 2018
    Publication date: February 20, 2020
    Applicants: Thomas Jefferson University, Imvax, Inc.
    Inventors: David W. Andrews, Douglas C. Hooper, Arthur Howe
  • Publication number: 20200046313
    Abstract: The present invention relates to the use of contrast-enhanced ultrasound using microbubble-based ultrasound contrast agents to accomplish noninvasive subharmonic aided pressure estimation (SHAPE) in a region of interest (ROI) of a subject. The method of the invention provides a non-invasive, direct, and accurate method for pressure estimation.
    Type: Application
    Filed: October 11, 2017
    Publication date: February 13, 2020
    Applicants: THOMAS JEFFERSON UNIVERSITY, GE HEALTHCARE LIMITED
    Inventors: Flemming Forsberg, David Mills, John R. Eisenbrey, Kirk Wallace, Ipshita Gupta
  • Publication number: 20200046708
    Abstract: A method of reducing the severity of abdominal adhesion due to surgical complications comprising: administering to said patient at least a first dose of trametinib between 0.01 mg to 2.0 mg, and after said surgical procedure, administering to said patient a further dose of trametinib between 0.01 mg to 2.0 mg, daily, for at least seven days post-surgery.
    Type: Application
    Filed: April 20, 2018
    Publication date: February 13, 2020
    Applicant: Thomas Jefferson University
    Inventors: Joel Rosenbloom, Edward John Macarak
  • Publication number: 20200038429
    Abstract: Provided herein are methods of treating cancer or an autoimmune disease comprising administering a liposome that comprises neutral phospholipids and a P-ethoxy oligonucleotide that targets a IGF-1R-encoding polynucleotide.
    Type: Application
    Filed: April 19, 2018
    Publication date: February 6, 2020
    Applicants: Bio-Path Holdings, Inc., Thomas Jefferson University
    Inventors: Ana Ashizawa, Douglas Craig Hooper, David W. Andrews
  • Patent number: 10543226
    Abstract: The present disclosure provides pharmaceutical compositions comprising nucleic acids capable of targeting IGF-1R expression in M2 cells. The present disclosure also provides methods for the selective reduction of M2 cells by targeting expression of IGF-1R in these cells. The present disclosure further provides methods for treating cancer and enhancing therapeutic by targeting expression of IGF-1R in M2 cells in patients. The pharmaceutical composition of the present invention is effective when administered systemically to subjects in need thereof. The ease of administration of the pharmaceutical composition facilitates treatment and enhances patient compliance.
    Type: Grant
    Filed: January 10, 2018
    Date of Patent: January 28, 2020
    Assignee: Thomas Jefferson University
    Inventors: David W. Andrews, Douglas C. Hooper